Today's Rundown Hung, ex-Medivation execs join forces for stealthy cancer startup GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test Ophthotech (now Iveric) hits eye drug goals as shares jump for tiny biotech [Sponsored] RenMab™ Mouse: a leading platform for fully human antibody generation Merus charts early promise for cancer drug targeting NRG1 fusions Biopharma's top broken, unfulfilled or abandoned promises Featured Story | | | Monday, October 28, 2019 David Hung, M.D., has had a strange few years: Going from the man who led Medivation into being snapped up by Pfizer in a major $14 billion M&A deal, he then went over to Axovant, where it went very wrong. |
|
|---|
|
| | White Paper: Rise in Targeted Therapies Biologics have experienced steady double-digit growth over the last 15 years. Precision medicine is also on the rise. Learn more about what to look for when navigating this new era of small-volume manufacturing. |
Top Stories Monday, October 28, 2019 It won’t stuff your pockets with profits and it’s not sexy, but GlaxoSmithKline is pushing forward into a phase 3 for its antibiotic work as governments continue to sound the alarm of an antibiotic-resistant future. Monday, October 28, 2019 While pivoting to gene therapies, microcap Iveric bio (once Ophthotech) has posted positive data from its key eye drug Zimura (avacincaptad pegol). Monday, October 28, 2019 Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts, authentic position within the chromosome. Monday, October 28, 2019 Netherlands-based Merus revised its clinical trial plans for its bispecific antibody zenocutuzumab this summer, in light of data showing the drug’s efficacy in targeting a rare but aggressive gene abnormality. Now the company says it has strong evidence it’s on the right path—though, admittedly, it’s very early evidence. Monday, October 28, 2019 CEOs for Bayer, AbbVie, Allergan and other companies others appear in our report featuring the top broken promises in biopharma. | | QUALITY. SPEED. VALUE.
You Can Have All Three We deliver potent, picomolar-affinity, development-ready human antibodies in a greater number and a shorter timeline than other CROs using transgenic animals, in vitro display or humanization, including for difficult targets such a GPCRs. Contact us at info@alivamab.com to learn more. alivamab.com |
Resources Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 